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The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia organised a 
one day international conference on the value of innovation in decision-making in health care 
in Central and Eastern Europe. The focus of the conference was on reimbursement decisions 
for medicines using health technology assessment and the use of managed entry agreements 
(MEAs). The objectives of this conference were firstly to discuss the challenges and 
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opportunities with the use of MEAs in Central and Eastern European countries; secondly the 
role of patient registries especially with outcome based schemes, and finally new approaches 
to improve accessibility to new medicines including better managing their entry. 
 
Background 
Central and Eastern European (CEE) health care systems are faced with a number of 
challenges through ageing populations, rising patient expectations and constrained resources 
(1). Improving access to new and valued innovative technologies within increasingly 
constrained budgets is becoming very difficult. For example, there are concerns regarding the 
LPSDFWRIGHOD\VLQHYDOXDWLQJQHZWHFKQRORJLHVRQSDWLHQWV¶KHDOWKDVZHOODVFRncerns that 
current high patient co-payments for medicines, including biological medicines, restricts their 
use (2, 3). The lack of transparency in some countries can also make interpreting decision 
making challenging (4).  
 
Tanja Novakovic (Pharmaceutical Association of Serbia) introduced the key concept of value 
in evaluating health innovations and challenges for decision-making. This is not helped by a 
lack of an agreed definition of innovation (5, 6). She presented data from IMS Health 
International Comparison of the Serbian Market showing that since 2010, 139 new medicines 
were registered in the EU. Out of these, Bulgaria reimbursed 44, Croatia 27 and Serbia only 
1. After a 5 year wait in Serbia, the Managing Board of the National Health Insurance Fund 
approved 23 innovative drugs for inclusion onto the Positive Drug List (7). 18 drugs were 
subsequently also included on the list of medicines with Managed Entry Agreements (MEAs) 
and the remaining five drugs intended for the treatment of children were reimbursed without 
restrictions on their use. 
 
Managed Entry Agreements 
Alessandra Ferrario (Harvard University) discussed the use of MEAs as instruments which 
may be implemented to address issues of uncertainty around effectiveness, cost-effectiveness 
and uptake in real-life and/or high prices affecting decision-making processes. Different 
MEAs, both financial and health-outcome based, can be used to modulate effectiveness, e.g. 
coverage with evidence development, price such as discounts and free doses, payment by 
result, and the use, e.g. registries, of medicines which in turn influence two key decision-
making criteria, cost-effectiveness and budget impact (8, 9). 
 
Studies have found that MEAs are widely implemented among Western countries and more 
recently in a number of CEE countries. Ferrario presented the results of a 2017 survey on the 
implementation of MEAs in sixteen CEE countries. All countries with MEAs in place (10) 
implemented different types of financial agreements. Eight countries (Bulgaria, Croatia, 
Czech Republic, Estonia, Hungary, Latvia, Poland and Romania) allowed for the 
implementation of health-outcome based MEAs. Ferrario highlighted issues related to the 
administrative burden of their implementation, price transparency and raised the need for a 
monitoring framework to evaluate their impact. According to Ferrario, MEAs should be seen 
as a stepping stone that could contribute to improving access to new medicines while working 
towards sustainable solutions to ensure equitable access to affordable medicines for all 
eligible patients throughout CEE countries. 
 
BojanTrkulja (The Association of the manufacturers of innovative drugs in Serbia) presented 
examples of the Serbian experience with implementation of MEAs. Trkulja highlighted that 
for MEAs to be truly successful, several principles must be met. This includes simplicity to 
avoid substantial monitoring and implementation costs. Moreover, Trkulja highlighted the 
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need for clarity, whether this relates to providing more evidence relating to clinical outcomes, 
estimating population sizes, offsetting costs, assessing the budget impact or the cost-
effectiveness of the new medicine at the list price. In addition, MEAs should be tailored to 
the particular setting, therapeutic area and product requirements. MEA schemes should also 
enable payers to optimise recommendations regarding new and existing technologies in a 
consistent and rational manner aided by transparency and trust between parties to ensure 
more efficient decision-making (11).  
 
Managed Entry Agreements and Health Technology Assessment 
Krzysztof Landa (National Center of Research & Development, Poland) introduced an 
alternative reimbursement mode for development (RMD) whereby a country not only 
purchases goods or medicines but also attracts companies to invest in production and R&D. 
Industry investments within the country may provide additional employment opportunities 
and have a positive multiplier effect for other parts of the host economy. RMD uses the 
incremental cost-utility ratio (ICUR) as a tool to enhance industrial investments in the host 
country. The concept is that a pharmaceutical company may improve its chances of success 
in gaining a positive reimbursement decision if the company already provides significant 
contributions to the host economy. It is feasible to multiply the effective cost of a new 
technology by the RMD factor while assessing its cost-utility against a comparator. This aims 
to persuade pharmaceutical companies to provide greater investment into the host country 
and in return the company receives more favourable reimbursement conditions.  
 
Dávid Dankó (Corvinus University of Budapest) discussed links between MEAs and health 
technology assessment (HTA), raising the point that MEAs help mitigate clinical and 
economic uncertainties regarding new health technologies. However, without HTA they may 
be suboptimal health outcomes if the uncertainty and risks surrounding the use of new 
technologies is not fully evaluated (12). The pricing and reimbursement process must be 
constructed in a way that HTA fully captures relevant uncertainties so that MEA negotiations 
can be seamlessly connected to, or even integrated into, the technology assessment and 
appraisal phase. This enhances the role of a deliberative element in the decision process and 
is likely to introduce a negotiating element into it. 
 
Real world evidence and accessibility to new medicines 
Jaroslav Duba (OAKS Consulting) discussed the role of patient registries in facilitating 
access to medicines. For originator products, or in case of a new indication, it is mandatory to 
submit data from clinical trials as well as cost-effectiveness and budget impact analyses in the 
Czech Republic. Real-World Evidence (RWE) data is an important component for successful 
reimbursement. The Czech Republic is a leader in providing RWE as there is free access to 
anonymised public information and there has been a significant rise in the number of 
UHJLVWULHVLQUHFHQW\HDUV6RPHRIWKHVHKDYHEHFRPHSDUWRIWKHµ1DWLRQDO+HDOWKFDUH
,QIRUPDWLRQ6\VWHP¶(13). In the Czech Republic, currently four sources of data can be used 
for RWE. These include specific disease area registries, health care providers, payers (Data 
SURYLGLQJEDVHGRQ³Freedom of information law 106/1999 Col´DQGSXEOLFDGPLQLVWUDWLRQ
Consequently, there is great potential for combining clinical data and RWE data at national 
level in the Czech Republic, and potentially wider across the CEE region depending on 
available data sets. 
 
Antony Martin (Liverpool University) emphasized the importance of ensuring equitable 
access to innovations in health care. Minimizing modifiable health disparities is fundamental 
for an equitable and progressive achievement of health care coverage (14). However, there 
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are concerns that there can be differences in uptake of new innovative medicines in terms of 
both speed of access and the number of patients treated, which may be  different in different 
populations and CEE countries due to challenges in access, ability to pay, availability and 
understanding of health information (15). This needs to be addressed where possible (14). 
Moreover, an assessment of how innovations in medicine translate within different subgroups 
is paramount to enhance their potential funding (16), as well as ensure that the beneficial 
aggregate population effects do not conceal widening disparities (17).  
 
Health care financing considerations 
Simo Vukovic (Ministry of Health, Serbia) discussed major reforms which have been 
conducted related to the introduction of diagnosis-related group (DRG) systems in Serbia. 
The new payment system will help with auditing, introduce new types of payments, and 
increase fairness of payments. The current payment system has been based on the traditional 
healthcare payment fee-for-service model that requires patients or payers to reimburse the 
healthcare provider for each service performed. Consequently, there has been no incentive to 
implement preventative care strategies, prevent hospitalization or introduce cost-saving 
measures. The objective of DRGs is to develop a classification system that identifies the 
"products" that the patient receives rather than inputs. Moreover, hospital revenues will more 
closely reflect the cost of good care. DRGs provide an opportunity to better control health 
care expenditure, increase activity levels and standardise care. In addition, the DRG system 
provides valuable data for the analysis and comparison of hospital performances across the 
system.  
 
Nikolaos Kotsopoulos (University of Athens) described the public economic consequences of 
health and investments in health care using a number of case studies (18-20). Dr Kotsopoulos 
GLVFXVVHGKRZDµJRYHUQPHQWSHUVSHFWLYH¶framework that accounts for transfer costs and lost 
tax revenues might be suitable for quantifying the benefits of healthcare in tax-financed 
public health systems. To address the value of health and health care investments for 
governments, a fiscal health analytic framework that captures how changes in morbidity and 
mortality influence tax revenue and transfer costs, e.g. disability, allowances, ongoing health 
costs, was described. The framework can be used to evaluate the marginal impact of discrete 
investments or a mix of interventions in healthcare to inform budgetary consequences. In this 
context, the framework can be considered as a fiscal budget impact, and/or cost-benefit 
analysis model that accounts for how morbidity and mortality linked to specific programs 
represent both ongoing costs and tax revenue for government.  
 
Conclusions 
Innovations can drive increased spending in health care as a result of substitution of lower 
priced products with new higher priced technologies, complementarity effects, i.e. new and 
old products used concurrently, and by providing treatments for conditions for which 
previously no treatments were available. To achieve financial stability, two key challenges 
need addressing. Firstly, deciding on the level of available resources; secondly, ensuring 
optimal resource allocation within finite budgets. To be relevant to decision making in the 
CEE region, governments and HTA agencies must address these key challenges. 
 
MEAs may be one part of addressing financial stability in the region. But to be effective, 
MEAs should be applied together with HTA, so they can help address clinical and economic 
uncertainties and provide a transparent and timely framework for deliberative decision-
making. However, a current challenge is that most MEAs implemented in the CEE region 
involve confidential pricing arrangements, and there are few publications assessing their 
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impact. Further, there can be a reluctance among companies to make decision making more 
transparent as seen in Poland. 
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